Published in Breast J on February 26, 2007
Benign breast disease and subsequent breast cancer: English record linkage studies. J Public Health (Oxf) (2010) 0.82
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med (2003) 3.46
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 2.81
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med (2016) 2.72
Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res (2007) 2.71
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci U S A (2007) 2.70
MR elastography of breast cancer: preliminary results. AJR Am J Roentgenol (2002) 2.65
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol (2005) 2.09
Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol (2008) 2.06
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res (2011) 2.02
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Current management strategies for ovarian cancer. Mayo Clin Proc (2007) 1.94
Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 1.90
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol (2009) 1.82
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol (2002) 1.79
Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med (2006) 1.77
Association between mammographic density and age-related lobular involution of the breast. J Clin Oncol (2010) 1.70
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer (2004) 1.64
A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology (2012) 1.56
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol (2004) 1.47
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) (2011) 1.45
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest (2006) 1.37
Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res (2014) 1.35
Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer (2008) 1.34
Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia (2009) 1.32
Inherited determinants of ovarian cancer survival. Clin Cancer Res (2010) 1.32
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer (2008) 1.28
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.26
Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. Mayo Clin Proc (2003) 1.26
Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat (2009) 1.25
Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.25
Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene (2005) 1.24
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol (2006) 1.24
Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol (2009) 1.23
Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst (2010) 1.23
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One (2013) 1.22
Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol (2010) 1.21
Translating evidence-based information into effective risk communication: current challenges and opportunities. J Lab Clin Med (2005) 1.19
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol (2010) 1.16
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) (2014) 1.13
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res (2003) 1.12
Lobular involution: localized phenomenon or field effect? Breast Cancer Res Treat (2008) 1.12
Breast biopsy utilization: a population-based study. Arch Intern Med (2005) 1.12
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer (2003) 1.11
Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol (2004) 1.10
Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem (2007) 1.09
Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol (2011) 1.07
Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07
An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol (2006) 1.06
Breast manifestations of systemic diseases. Int J Womens Health (2012) 1.05
Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat (2011) 1.05
Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res (2012) 1.03
Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat (2007) 1.03
Relative weight at age 12 and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.03
Paget's disease of the breast: accuracy of preoperative assessment. Breast Cancer Res Treat (2006) 1.02
Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol Genet (2011) 1.00
Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol (2009) 0.99
Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat (2014) 0.99
Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc (2005) 0.99
Pseudoangiomatous stromal hyperplasia and breast cancer risk. Ann Surg Oncol (2010) 0.98
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum Mol Genet (2013) 0.97
Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer (2003) 0.96
Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One (2009) 0.96
Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat (2010) 0.94
Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Res Treat (2011) 0.94
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol (2011) 0.93
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer (2009) 0.93
Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One (2013) 0.93
Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol (2010) 0.92
Factors associated with surgical decision making in women with early-stage breast cancer: a literature review. J Womens Health (Larchmt) (2013) 0.92
Qualitative and quantitative analysis of women's perceptions of transvaginal surgery. Surg Endosc (2011) 0.90
Risk of ovarian cancer and inherited variants in relapse-associated genes. PLoS One (2010) 0.90
Immunomagnetic diffractometry for detection of diagnostic serum markers. J Am Chem Soc (2007) 0.90
Benign breast disease and the risk of subsequent breast cancer in African American women. Cancer Prev Res (Phila) (2012) 0.89
Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer (2003) 0.88
Patient understanding of the revised USPSTF screening mammogram guidelines: need for development of patient decision aids. BMC Womens Health (2012) 0.88
Impact of reconstruction and reoperation on long-term patient-reported satisfaction after contralateral prophylactic mastectomy. Ann Surg Oncol (2014) 0.88
Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res (Phila) (2011) 0.88
Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. Twin Res Hum Genet (2010) 0.87
Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer Detect Prev (2004) 0.85
Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. Cancer Epidemiol Biomarkers Prev (2012) 0.85
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res (2008) 0.85